Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 2
2005 1
2006 2
2009 1
2010 3
2011 2
2013 1
2014 2
2015 4
2016 6
2017 3
2018 3
2019 4
2020 3
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenetics of siponimod: A systematic review.
Díaz-Villamarín X, Piñar-Morales R, Barrero-Hernández FJ, Antúnez-Rodríguez A, Cabeza-Barrera J, Morón-Romero R. Díaz-Villamarín X, et al. Among authors: cabeza barrera j. Biomed Pharmacother. 2022 Sep;153:113536. doi: 10.1016/j.biopha.2022.113536. Epub 2022 Aug 12. Biomed Pharmacother. 2022. PMID: 36076616 Free article. Review.
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Ríos-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, de la Guardia AMDVD, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J. Ríos-Tamayo R, et al. Among authors: cabeza barrera j. Drug Des Devel Ther. 2017 Aug 22;11:2399-2408. doi: 10.2147/DDDT.S115456. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860711 Free PMC article. Review.
Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Cabeza Barrera J, Faus-Dáder MJ. Pérez-Ramírez C, et al. Among authors: cabeza barrera j. Mutat Res Rev Mutat Res. 2019 Jul-Sep;781:63-70. doi: 10.1016/j.mrrev.2019.04.001. Epub 2019 Apr 9. Mutat Res Rev Mutat Res. 2019. PMID: 31416579 Free article. Review.
Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.
Fernández-López C, Expósito-Hernández J, Arrebola-Moreno JP, Calleja-Hernández MÁ, Expósito-Ruíz M, Guerrero-Tejada R, Linares I, Cabeza-Barrera J. Fernández-López C, et al. Among authors: cabeza barrera j. Cancer Med. 2016 Sep;5(9):2190-7. doi: 10.1002/cam4.782. Epub 2016 Jul 23. Cancer Med. 2016. PMID: 27449070 Free PMC article. Review.
Cutaneous leishmaniasis associated with TNF-α blockers: a case report.
Nieto Gómez P, Casas Hidalgo I, Casas Hidalgo MP, Álvarez Sánchez R, Rodríguez Delgado A, Cabeza-Barrera J. Nieto Gómez P, et al. Among authors: cabeza barrera j. Eur J Hosp Pharm. 2019 Jul;26(4):233-234. doi: 10.1136/ejhpharm-2018-001521. Epub 2018 May 5. Eur J Hosp Pharm. 2019. PMID: 31338176 Free PMC article.
Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications.
Núñez-Núñez M PharmD, MsC, Casas-Hidalgo I, García-Fumero R, Vallejo-Rodríguez I, Anguita-Santos F, Hernández-Quero J, Cabeza-Barrera J, Ruiz-Sancho A. Núñez-Núñez M PharmD, MsC, et al. Among authors: cabeza barrera j. Eur J Hosp Pharm. 2020 Sep;27(5):310-312. doi: 10.1136/ejhpharm-2018-001711. Epub 2018 Nov 26. Eur J Hosp Pharm. 2020. PMID: 32839266 Free PMC article.
38 results